7 results

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo

Journal Article
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (2020)
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, 26, 1965-1980. https://doi.org/10.1007/s10989-019-09994-1
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Ov...

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections

Presentation / Conference
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September)
Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece
Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Red...

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016)
Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0
Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biom...

Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents.

Journal Article
Dias, N., Goossens, J., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., …Bailly, C. (2005)
Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry, 16(4), 949-958. https://doi.org/10.1021/bc050065x
We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derive...

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model

Journal Article
Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B., & Vanderkerken, K. (2005)
Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia, 19(9), 1628-1633. https://doi.org/10.1038/sj.leu.2403866
Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix me...

Anthracene derivatives as anti-cancer agents.

Patent
Mincher, D. & Turnbull, A. (2004)
Anthracene derivatives as anti-cancer agents.
The present invention relates to compounds which are based on an anthraquinone nucleus for use in medicine, particularly as anti-cancer agents which exert their effects throug...

Stereospecific synthesis of chiral caprolactone monomers from D-glucose.

Journal Article
Defossemont, G. & Mincher, D. (2003)
Stereospecific synthesis of chiral caprolactone monomers from D-glucose. Carbohydrate Research. 338, 563-565. doi:10.1016/S0008-6215(02)00490-1. ISSN 0008-6215
The synthesis and characterisation of a novel chiral bicyclic oxacaprolactone is reported. The choice of diisopropylidene- -glucose as a starting material allowed selective in...
20 results

Design of novel candidate PDK-X selective inhibitors as new drugs for the treatment of endometrial cancer, endometriosis and related conditions

2023 - date
Amy Dillon | Director of Studies: Dr David Mincher | Second Supervisor: Dr Craig Stevens

Design of a new fluorogenic molecular probe of lipases that will be specific for monoacylglycerol lipase

2021 - date
Judith Ajaezu | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, Synthesis and modelling of intracellularly targeted anticancer agents.

2021 - date
Aziz Kiran | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and cytotoxicity of bifunctional anticancer agents targeted to mitochondria.

2018 - date
Mohamad Kamel | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design and development of novel targeted anticancer drugs

2018 - date
Ewoma Akpughe | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

A global exploration of programme theory within surf therapy

2018 - 2022
Dr James Marshall | Director of Studies: Dr Brendon Ferrier | Second Supervisor: Prof Russell Martindale

Communities of constraint: An ethnographic study of Tibetan refugees navigating protracted displacement and everyday vulnerability in Nepal

2018 - date
Kyle Schwartz | Director of Studies: Dr Kiril Sharapov | Second Supervisor: Prof Richard Whitecross

Synthesis and flourescence properties of a novel legumain substrate probe

2018 - 2022
Deepthi Ravula | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and biological evaluation of novel targeted anthelmintic agents

2015 - 2020
Aiman Rehan | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and evaluation of novel and clinically used anti-cancer agents targeted intracellularly

2014 - 2021
The majority of clinically used anticancer drugs suffer from poor selectivity for tumour cells ...
Omar Mohammed | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Date


Date